GlycoMimetics, Inc. (GLYC)
NASDAQ: GLYC · Real-Time Price · USD
0.410
+0.027 (7.16%)
At close: Nov 4, 2024, 4:00 PM
0.392
-0.018 (-4.44%)
Pre-market: Nov 5, 2024, 9:20 AM EST

Company Description

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States.

It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.

The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein.

In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma.

The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687.

GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GlycoMimetics, Inc.
GlycoMimetics logo
Country United States
Founded 2003
IPO Date Jan 10, 2014
Industry Biotechnology
Sector Healthcare
Employees 35
CEO Harout Semerjian

Contact Details

Address:
9708 Medical Center Drive
Rockville, Maryland 20850
United States
Phone 240 243 1201
Website glycomimetics.com

Stock Details

Ticker Symbol GLYC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001253689
CUSIP Number 38000Q102
ISIN Number US38000Q1022
SIC Code 2834

Key Executives

Name Position
Harout Semerjian Chief Executive Officer, President and Director
Rachel K. King Co-Founder and Director
Brian M. Hahn Senior Vice President and Chief Financial Officer
Dr. Edwin Rock M.D., Ph.D. Senior Vice President and Chief Medical Officer
Stephanie R. Irish CPA Vice President of Accounting
Christian B. Dinneen-Long General Counsel and Company Secretary
Bruce Johnson Senior Vice President and Chief Commercial Officer
Chinmaya Rath Senior Vice President and Chief Business Officer
Shantha Tyavanagimatt Ph.D. Senior Vice President of Technical Operations

Latest SEC Filings

Date Type Title
Nov 4, 2024 SC 13D General statement of acquisition of beneficial ownership
Nov 4, 2024 SCHEDULE 13G/A Filing
Oct 29, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Oct 29, 2024 8-K Current Report
Aug 15, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 14, 2024 SCHEDULE 13G Filing
Aug 8, 2024 10-Q Quarterly Report
Jul 30, 2024 8-K Current Report
Jul 29, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jun 26, 2024 8-K Current Report